Search Results - Xujie Yu

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia by Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Yan Li, Daniel W. Pierce, Evelyn Barnett, Jeffrey Marine, Monika Miranda, Ada Azaryan, Xujie Yu, Pilar Nava-Parada, Jay Mei, Thomas J. Kipps

Get full text